

21. The nucleic acid as claimed in claim 19 or 20, which nucleic acid is specifically bound to the Ras binding domain of the target protein of Ras.

22. The nucleic acid as claimed in any of claims 19 to 21, wherein the target protein of Ras is Raf-1.

23. The nucleic acid as claimed in claim 22, which nucleic acid is an RNA that is specifically bound to a Ras binding domain (R&D) of Raf-1.

24. The nucleic acid as claimed in any of claims 20 to 22, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

25. The nucleic acid as claimed in claim 24, wherein the RNA is an RNA containing at least any one of base sequences of sequence Nos. 1 to 8 or sequence Nos. 25 to 28 of Sequence Listing or a base sequence in which at least one base thereof is deleted and substituted with another base and/or at least one base is added.

26. A nucleic acid having a complementary base sequence to the nucleic acid as claimed in claim 24 or 25.

27. An agent for controlling cell signal transduction which agent is made of the nucleic acid as claimed in any of claims 19 to 26.

28. The controlling agent as claimed in claim 27, wherein the nucleic acid is an RNA.

29. A method of controlling cell signal transduction using the nucleic acid as claimed in any of claims 19 to 26.

30. The method as claimed in claim 29, wherein the nucleic acid is an RNA.

31. A pharmaceutical composition containing the nucleic acid as claimed in any of claims 19-26.

32. The pharmaceutical composition as claimed in claim 31, which composition is used for treating cancers or inflammatory diseases.

33. A method of selecting an RNA having an ability of specific binding to a target protein of Ras, which comprises selecting the RNA having the ability of specific binding to the target protein of Ras from an RNA pool having various base sequences.

34. The method as claimed in claim 33, wherein the RNA of the RNA pool having various base sequences is an RNA comprising 20 to 300 bases.

35. The method as claimed in claim 33 or 34 wherein the target protein of Ras is Raf-1.

Respectfully submitted,



Peter F Corless, Reg. No.(33.860)
DIKE, BRONSTEIN, ROBERTS &
CUSHMAN, L.L.P.

130 Water Street
Boston, Massachusetts 02109-4280
Tel. (617) 523-3400
Fax (617) 523-6440

Dated: 4/11/00